A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

OBJECTIVES: To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy. METHODS: This is a phase III, randomised, double-blind, parallel-group, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M, Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264222/
https://www.ncbi.nlm.nih.gov/pubmed/26150601
http://dx.doi.org/10.1136/annrheumdis-2015-207588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264222/
https://www.ncbi.nlm.nih.gov/pubmed/26150601
http://dx.doi.org/10.1136/annrheumdis-2015-207588

Ejemplares similares